Bryce Istvan News & Views

Updated 3 months ago   More news & views
Today's NPS Deal- Putting Drugs In The Right Hands External-link
By Bryce Istvan:Today NPS Pharmaceuticals (NPSP) repurchased the ex-North America rights to its two main orphan drugs, Gattex/Revestive for the treatment of short bowel syndrome and Preotact/Natpara for hypoparathyroidism from Takeda (TKPHF.PK). In exchange for repurchasing the rights, NPS is giving Takeda $50,000,0...
Comments Comment
Source: Seeking Alpha
Mar 19, 2013 - 6:31 AM
Browse Related Topics:   America Complete St... Nps Genzyme More    
Questcor Drops On Headline Misunderstanding External-link
By Bryce Istvan:Questcor (QCOR) tanked just after the open today, falling as much as 15% after a headline crossed the wires from Benzinga stating that a synthetic version of Acthar had been approved by the FDA. The headline was quickly pulled and has now been replaced to reflect the correct information, that the dru...
Comments Comment
Source: Seeking Alpha
Nov 02, 2012 - 4:56 AM
Browse Related Topics:   U.S. Europe Fda Benzinga
NPS Pharmaceuticals: Preparing For Tuesday's Advisory Committee Meeting External-link
By Bryce Istvan:NPS Pharmaceuticals (NPSP) is getting a nice boost after the FDA published its briefing documents ahead of Tuesday's Gastrointestinal Advisory Committee meeting on Gattex. For Advisory Committee meetings the FDA brings in a panel of industry experts to discuss safety and efficacy concerns and vote on...
Comments Comment
Source: Seeking Alpha
Oct 12, 2012 - 5:42 AM
Browse Related Topics:   Nps Fda Npsp Advisory Co... More    
Amgen's Xgeva Prostate Indication Expansion Could be Blockbuster On Its Own External-link
By Bryce Istvan:Xgeva, part of the Denosumab family, is Amgen’s (AMGN) latest bone related drug. Its current indication is for the treatment of skeletal related events (SREs) caused by bone metastases in all cancers excluding multiple myelomas. These metastases are incredibly common in advanced stages of prostate ca...
Comments Comment
Source: Seeking Alpha
Jan 10, 2012 - 5:24 AM
Browse Related Topics:   Amgen Iii Complete St... Prolia More    
Targacept: What's Left After Latest TC-5214 Disappointment? External-link
By Bryce Istvan:Today AstraZeneca (AZN) and Targacept (TRGT) announced the results from their second of four Phase 3 trials for TC-5214, a depression drug. The results failed to meet the primary endpoint based on change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score after eight weeks of adjunct...
Comments Comment
Source: Seeking Alpha
Dec 20, 2011 - 12:02 AM
Browse Related Topics:   Astra Zeneca
Five Drugs That Own The Prostate Pipeline External-link
By Bryce Istvan:Prostate cancer, the second most common cancer diagnosed in men, stole the drug headlines last week. Over two million men in the U.S. are currently living with prostate cancer. In 2011 there will be an estimated 240,000 new cases diagnosed and almost 34,000 people will die from it, according to the A...
Comments Comment
Source: Seeking Alpha
Nov 07, 2011 - 6:21 PM
Browse Related Topics:   American Ca... U.S.
5 Drugs That Own The Prostate Pipeline External-link
By Bryce Istvan:Prostate cancer, the second most common cancer diagnosed in men, stole the drug headlines last week. Over two million men in the U.S. are currently living with prostate cancer. In 2011 there will be an estimated 240,000 new cases diagnosed and almost 34,000 people will die from it, according to the A...
Comments Comment
Source: Seeking Alpha
Nov 07, 2011 - 6:21 PM
Browse Related Topics:   American Ca... U.S.
NPS Pharmaceuticals Gets Good News (Finally) External-link
By Bryce Istvan:NPS Pharmaceuticals (NPSP), after taking a beating last week on a Gattex cancer scare, received good news this morning when it released Phase 3 trial results for NPSP558. NPSP558, now being called Natpara, is a bio-engineered replica of human parathyroid hormone (rh-PTH 1-84) used to treat hypoparath...
Comments Comment
Source: Seeking Alpha
Nov 07, 2011 - 9:07 AM
Browse Related Topics:   U.S. Complete St... Nps Npsp More    
NPS Pharmaceuticals' Selloff Was Overdone External-link
By Bryce Istvan:NPS Pharmaceuticals (NPSP) is trading down over 30% yesterday after presenting new data on their drug GATTEX (teduglutide) for the treatment of short bowel syndrome. The data presented was generally favorable with 91% of test subjects responding to treatment. While the data was positive, investors we...
Comments Comment
Source: Seeking Alpha
Nov 01, 2011 - 4:53 AM
Browse Related Topics:   Hodgkin Npsp Nps Pharmac... Gattex
NPS Pharmaceuticals' Sell-Off Was Overdone External-link
By Bryce Istvan:NPS Pharmaceuticals (NPSP) is trading down over 30% yesterday after presenting new data on their drug GATTEX (teduglutide) for the treatment of short bowel syndrome. The data presented was generally favorable with 91% of test subjects responding to treatment. While the data was positive, investors we...
Comments Comment
Source: Seeking Alpha
Nov 01, 2011 - 4:53 AM
Browse Related Topics:   Hodgkin Npsp Nps Pharmac... Gattex
Leave a Comment about Bryce Istvan

Cancel
Be the first to leave a comment!

Bryce Istvan Videos